*Review* **Development of Macozinone for TB treatment: An Update**

**Vadim Makarov 1,\* and Katarína Mikušová <sup>2</sup>**


**\*** Correspondence: makarov@inbi.ras.ru

Received: 5 March 2020; Accepted: 25 March 2020; Published: 26 March 2020

**Abstract:** Macozinone, a piperazine-benzothiazinone PBTZ169, is currently undergoing Phase 1/2 clinical studies for the treatment of tuberculosis (TB). In this review we summarize the key findings that led to the development of this compound and to identification of its target, decaprenylphospohoryl ribose oxidase DprE1, which is involved in the synthesis of the essential arabinan polymers of the cell wall in a TB pathogen, *Mycobacterium tuberculosis*. We present the results of the pilot clinical studies, which raise optimism regarding its further development towards more efficient TB drug regimens.

**Keywords:** macozinone; DprE1 inhibitor; clinical studies
